ESPE Abstracts (2015) 84 P-3-1179

Plasma Visfatin Level and Its Association with Apolipoproteins A1 and B in Hypothyroid Children

Elham Hashemi Dehkordia,b, Noushin Rostampoura, Karamali Kasiric, Mohammad Moafid, Mohammad Esmail Arameshe & Mahin Hashemipourf

aDepartment of Pediatrics Endocrinology, Shahrekord University of Medical Sciences, Shahrekord, Iran; bDepartment of Pediatrics Endocrinology, Research Institute for Primordial Prevention of Non-Communicable Disease, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; cDepartment of Pediatrics Gastrology, Shahrekord University of Medical Sciences, Shahrekord, Iran; dDepartment of Immunology, PhD Student of Immunology, Bu-Ali Sina University, Hamadan, Iran; eDepartment of Pediatrics Endocrinology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran; fDepartment of Pediatrics Endocrinology, Isfahan University of Medical Sciences, Isfahan, Iran

Background and aim: Hypothyroidism could be accountable for cardiovascular diseases; hence, necessity of novel biomarkers being capable to predict patient’s status is indispensable. The aim of this study was to appraise alteration of plasma visfatin levels (as a newly discovered proteins) and its association with lipid profiles of hypothyroid patients.

Materials and methods: In this cross-sectional, descriptive, and analytical study, 30 children being 3–18 years with levels of serum TSH ≥6.4 mIU/l were enrolled. Initially T4, T3, TSH, anti-thyroid peroxidase (anti-TPO), anti-thyroglobolin (anti TG), visfatin, triglyceride, cholesterol, LDL, HDL, apolipoprotein A1 (ApoA1), and ApoB as well as BMI of every subject were determined and they were assigned either in overt or subclinical cohorts; afterwards, appropriate doses of levothyroxine were administered. Three months later, all of the above-mentioned criteria (except for anti-TPO and anti-TG) were assessed.

Results: Mean age of the patients, which included 16 females and 14 males, was 10.2±5.2 years, while subclinical cases exceeded overt hypothyroid patients (24 and six cases respectively). Anti-TPO subjects surpassed and anti TG ones (11 and eight individuals respectively). Patient’s treatment led to significant decrease of plasma visfatin, ApoB, TG, cholesterol, and LDL (P<0.05). Alternatively, HDL and ApoA1 increased as a result of our treatment (P<0.05); however, BMI remained unchanged. Not only before our treatment, but also after this procedure, plasma visfatin variations did not correlated with patient’s lipid profile (P>0.05).

Discussion and conclusion: This study showed that plasma visfatin could be suggested as a predictive risk factor of cardiovascular diseases in hypothyroid patients.

Article tools

My recent searches

No recent searches.